<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT941-8624</title>
	</head>
	<body>
		<main>
			<p>940218 FT  18 FEB 94 / International Company News: Bayer buys stake in US generic drugs group Bayer, the German chemicals group, is making a move into the fast-growing US generics drugs sector with the acquisition of a 28.3 per cent stake in Schein Pharmaceutical, a privately owned generics company based in Florham Park, New Jersey. Bayer, which signalled last month that a deal with a US generics company was likely to be sealed before the end of March, is paying Dollars 310m for the stake. The size of the holding may be increased gradually following a proposed listing of Schein's shares, Bayer said. The acquisition follows the purchase by Hoechst, Bayer's German rival, last autumn. Hoechst paid Dollars 546m for a 51 per cent stake in Copley, a generic and over-the-counter drugs manufacturer. Generic drugs are out-of-patent products, sold over the counter. Analysts noted yesterday that Bayer appeared to have done the better deal. Schein is four times bigger than Copley but the companies are both valued at DM1.1bn (Dollars 639m). Schein's turnover last year was Dollars 400m compared with DM52m at Copley. There was no indication of Schein's profitability other than a comment that returns on sales of leading manufacturers of generic drug manufacturers currently range between 10 and 20 per cent. Schein employs 1,700 people and produces 350 products. 'Our strategy is to safeguard and expand our position as one of the world's leading pharmaceuticals companies,' said Mr Manfred Schneider, Bayer's chief executive. 'We must therefore also become a force in the generics market, which has above average growth rates, especially in the US. 'Together we can not only greatly increase our presence in the market but we can also meet the challenges inherent in the changing healthcare market,' he added, 'at the same time offering the patients a comprehensive range of medicines.'</p>
		</main>
</body></html>
            